Indeed, a protease-resistant variant of SDF-1α significantly improves blood flow in a model of peripheral artery disease and exhibits greater potency for cardioprotection than wild-type SDF-1α after MI [113,115,116]. Here, CXCL12 is linked to peripheral arterial disease.